Piper Jaffray analyst Christopher Raymond noted that Allergan (AGN) and Molecular Partners disclosed data from two Phase 3 trials comparing the latest DARPin formulation to Lucentis in age-related macular degeneration, calling the data "decidedly a non-starter." While few Regeneron (REGN) investors have expressed concern to Raymond over looming DARPin data, any overhang that did exist due to worries about another potential Eylea competitor in the AMD space have "been effectively lifted" following the DARPin data, said the analyst. He remains a buyer of Regeneron shares and keeps an Overweight rating and $450 price target on the stock.